Insulin-like growth factor-binding protein 7(IGFBP-7) is a secreted glycosylated protein that contains three protein domain modules. IGFBP7 contains an N-terminal IGFBP domain, followed by a Kazal-type serine proteinase inhibitor domain and a C-terminal immunoglobulin-like C2-type domain. Human and mouse IGFBP7 are highly homologous and share 94% aa sequence identity. It is expressed in many normal tissues and in cancer cells. It is abundantly expressed in high endothelial venules (HEVs) of blood vessels in the secondary lymphoid tissues. It binds IGF and insulin with very low affinity and has been shown to enhance the mitogenic actions of IGF and insulin. IGFBP7 also has IGF/insulin-independent activities. It interacts with heparan sulfate proteoglycans, type IV collagen, and specific chemokines. It supports weak cell adhesion, promotes cell spreading on type IV collagen, and stimulates the production of the potent vasodilator PGI2. It modulates tumor cell growth and has also been implicated in angiogenesis.
Recombinant Mouse IGFBP-7 is produced by our Mammalian expression system and the target gene encoding Ser26-Leu281 is expressed with a 6His tag at the C-terminus.
This product is provided as lyophilized powder which is shipped with ice packs.
> 95 % as determined by reducing SDS-PAGE.
< 1.0 EU per μg as determined by the LAL method.
|Stability and Storage
Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
|AP Mol Mass
Lyophilized from a 0.2 μm filtered solution of PBS, 150mM Nacl, pH7.4.
Please refer to the printed manual for detailed information.